Stephens Consulting’s Nuvalent NUVL Stock Holding History

Stephens Consulting’s Portfolio NUVL Stock Details NUVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10	Closed	-$710	–	1717
2025 Q1	$710	Buy	+10	New	+$782	﹤0.01%	815

Other funds holding NUVL

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Stephens Consulting's NUVL Position: Q2 2025 in Review

Stephens Consulting sold out of Nuvalent (NUVL) in Q2 2025, closing a stake of 10 shares — an estimated $710 sold.

Stephens Consulting first reported a position in NUVL in Q1 2025 and held it in 1 quarter. The position peaked at $710 in Q1 2025. 209 funds tracked by Wall St. Rank hold NUVL as of Q2 2025.

Stephens Consulting reported no remaining Nuvalent position as of Q2 2025 after selling out during the quarter.
Stephens Consulting sold 10 Nuvalent shares in Q2 2025, an estimated $710.
Stephens Consulting first reported a position in Nuvalent in Q1 2025 and held it in 1 quarter.
Stephens Consulting's Nuvalent position peaked at $710 in Q1 2025.
209 funds tracked by Wall St. Rank held Nuvalent as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.